同时值得关注的是，医渡科技在国际多边合作舞台实现重要突破：上海合作组织国家多功能经贸平台 (上合家园)卫生可持续发展工作委员会近期正式成立，医渡科技成功入选组织成员单位;公司联合创始 人、CEO 徐济铭当选委员会第一届理事，双重认可标志着公司在国际数字健康合作领域的专业能力与 行业地位获得权威背书。 近年来，医渡科技的国际化战略布局稳步推进，业务和客户网络已拓展至全球六个地区。通过与当地政 府部门、医疗机构及科研院所深度协同，构建起了成熟的本土化合作生态，研发的智能化解决方案已广 泛落地于传染病监测预警、全民人口健康管理、AI 辅助诊疗、个性化健康管理等关键领域，持续以科 技力量赋能全球健康事业发展。 智通财经APP获悉，12月19日，医渡科技(02158)公告显示，当日以每股5.23港元的价格回购9.35万股， 回购金额约49万港元。12月以来，公司已回购11次，累计回购约344万股，总金额超1740万港元。以真 金白银持续夯实市场信心，彰显医渡科技对自身发展前景的坚定看好。 消息面上，医渡科技近期在行业认可与国际合作领域捷报频传。在香港城市大学数码医学研究院周年大 会上，公司创始人、董事长宫如璟女士获聘为 ...

医渡科技(02158)发布公告，于2025年12月19日斥资48.95万港元回购9.35万股。 ...

智通财经APP讯，医渡科技(02158)发布公告，于2025年12月19日斥资48.95万港元回购9.35万股。 ...

格隆汇12月19日丨医渡科技(02158.HK)公告，12月19日耗资48.9万港元回购9.4万股。 ...

表格類別： 股票 狀態： 新提交 公司名稱： 醫渡科技有限公司 呈交日期： 2025年12月19日 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) FF305 FF305 確認 根據《主板上市規則》第13.25C條 / 《GEM上市規則》第17.27C條，我們在此確認，據我們所知所信，第一章節所述的每項股份發行或庫存股份出售或轉讓已獲發行人董事會正式授權批准，並遵 照所有適用上市規則、法律及其他監管規定進行，並在適用的情況下： (註7) (i) 上市發行人已收取其在是次股份發行或庫存股份出售或轉讓應得的全部款項； (viii) 有關債券、借貸股份、票據或公司債券的信託契約/平邊契據經已製備及簽署，有關詳情已送呈公司註冊處處長存檔（如法律如此規定）。 第一章節註釋： 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | ...

智通财经APP获悉，如何让复杂的临床试验对参与者更"友好"，对管理者更"高效"？动动手指，临床试 验的访视安排、报销进度、用药服务即可一键掌握——这已不再是设想。近日，医渡科技(02158)与北 京大学肿瘤医院联合打造的临床试验管理体系(CTMS)移动端——"北肿临床试验"小程序正式上线。这 不仅将"以患者为中心"的理念落到了实处，更标志着临床试验管理在参与者体验、数据安全与执行效率 上实现了全面升级。 体验三大升级：让临床试验参与"省心又安心" 本次新上线的CTMS小程序是以试验参与者体验为出发点，实现从"管理导向"向"服务导向"的升级突 破，其深度融入微信生态，在移动端场景下为试验参与者带来了诸多便利： 在此坚实而广泛的合作基础上，CTMS临床研究管理系统作为一个符合GCP标准的全链路数智化管理平 台，为北肿提供了从项目立项、执行到结题的一站式解决方案。其价值已在实践中得到充分验证：通过 系统的流程标准化与全周期精细管控，北肿临床试验项目的平均立项启动时间显著缩短，效率优于行业 平均水平。 这一系列以参与者为中心的改进，标志着临床试验数字化从侧重机构内部流程管理，向兼顾外部参与者 服务体验的成功延伸。 该 ...

Core Insights - The integration of general AI into the medical field faces challenges in ensuring that algorithms understand clinical needs and can be effectively embedded into treatment processes, marking a critical transition from "usable" to "practical" AI in healthcare [6][8] Group 1: AI Development and Implementation - Yidu Technology is focusing on a systematic reconstruction aimed at clinical practicality, utilizing its self-developed medical domain model "YiduCore" to create a dual-platform solution combining big data and large models [6][8] - The AI platform aims to transform the raw capabilities of large models into "intelligent agents" that comply with medical standards, understand clinical workflows, and possess specialized knowledge [6][7] Group 2: Trust and Integration in Clinical Settings - To achieve reliable applications of medical AI, Yidu Technology emphasizes bridging the trust gap between patients, doctors, and AI through three core capabilities: a high-quality knowledge center, a comprehensive library of over 40 intelligent algorithms, and seamless integration into natural workflows [7][8] - The "Doctor Clinical Copilot" is designed as a lightweight plugin that integrates into doctors' workstations, facilitating real-time AI assistance in critical tasks such as medical record writing and treatment planning [7][8] Group 3: Practical Applications and Impact - Yidu Technology has developed intelligent applications that address specific clinical tasks, significantly altering the modes and efficiencies of diagnosis and treatment in specialized fields [8][9] - In cardiology, the AI platform integrates over 20 cardiovascular guidelines to provide real-time analysis and decision support, enhancing the efficiency of knowledge retrieval and diagnostic capabilities for urgent scenarios [8] - In oncology, the AI system has improved the accuracy of tumor staging assessments to 90% and reduced computational demands, while also creating a digital twin of a chest tumor expert to offer personalized consultations [8][9] Group 4: Future Outlook - Yidu Technology plans to continue leveraging its dual-platform solution and intelligent agent matrix to deepen its impact across more specialized fields, aiming to enhance the precision and efficiency of healthcare services [9]

Core Viewpoint - The company demonstrates strong confidence in its intrinsic value and long-term development through frequent share buybacks, signaling positive financial health and operational capabilities [1][2]. Group 1: Share Buyback Activity - The company has conducted its 10th share buyback announcement this month, repurchasing 190,000 shares at a price of HKD 5.13 per share, totaling approximately HKD 1 million [1]. - Cumulatively, the company has repurchased 3.34 million shares in December, amounting to around HKD 17 million [1]. - Frequent and sustained buyback operations reflect the company's belief that its current stock price is undervalued [2]. Group 2: Business Development and Industry Engagement - The company has joined the Health Sustainable Development Working Committee under the Shanghai Cooperation Organization's economic platform, enhancing its role in international healthcare collaboration and innovation [1]. - The company has surpassed 3 million participants in the "Beijing Universal Health Insurance" program for 2026, showcasing its strong operational capabilities and market recognition in the health insurance sector [1]. - The company has been elected as the vice-chair unit of the Smart Healthcare Working Committee of the China Internet Association, further solidifying its industry influence and technological leadership [1]. Group 3: Financial Performance - The company reported steady revenue growth in its mid-term results for the 2026 fiscal year, nearing breakeven [1]. - Significant improvement in key financial metrics is attributed to the continuous increase in gross margin of core business and enhanced operational efficiency [1]. - The company's improved financial health reflects its strengthened commercialization capabilities and substantial progress in operational quality [1].

Core Viewpoint - The company, Yidu Tech (2158.HK), demonstrates strong confidence in its intrinsic value and long-term development through frequent share buybacks, totaling 3.34 million shares for approximately 17 million HKD in December alone [1][2]. Group 1: Share Buyback Activity - Yidu Tech announced its 10th share buyback in December, repurchasing 190,000 shares at a price of 5.13 HKD per share, amounting to about 1 million HKD [1]. - Cumulatively, the company has repurchased 3.34 million shares in December, with a total expenditure of approximately 17 million HKD [1]. - The frequent buyback actions are interpreted as a sign of the company's belief that its current stock price is undervalued and reflects its financial strength to support future strategic investments [2]. Group 2: Business Expansion and Industry Engagement - Yidu Tech has joined the Health Sustainable Development Working Committee under the Shanghai Cooperation Organization's economic and trade platform, aiming to enhance international cooperation and innovation in the healthcare sector [1]. - The company has surpassed 3 million participants in the "Beijing Universal Health Insurance" program for 2026, showcasing its operational capabilities in the public health insurance sector [1]. - Yidu Tech has been elected as the deputy chairman unit of the Smart Medical Committee of the China Internet Association, indicating its growing influence in the industry [1]. Group 3: Financial Performance - The mid-term financial results for the fiscal year 2026 show that Yidu Tech's revenue continues to grow, nearing a break-even point [1]. - The improvement in this key financial metric is attributed to the sustained increase in gross margin from core business operations and enhanced operational efficiency, reflecting significant progress in commercialization and operational quality [1].

Group 1 - The article reports on share buybacks conducted by various companies on December 18, 2025, with Tencent Holdings leading in both the number of shares repurchased and the total amount spent [1] - Tencent Holdings repurchased 1.055 million shares for a total of 636 million yuan, representing 1.030% of its total share capital for the year [2] - Other notable companies involved in the buyback include Xiaomi Group, which repurchased 3.75 million shares for 151 million yuan, and China National Petroleum Corporation, which repurchased 254,000 shares for 116.38 million yuan [3] Group 2 - The total number of shares repurchased by companies varied significantly, with China National Petroleum Corporation having a cumulative buyback of 230 million shares, which is 0.190% of its total share capital [3] - Companies like IGG and VITASOY also participated, with IGG repurchasing 182,000 shares for 68.49 million yuan and VITASOY repurchasing 122,000 shares for 77.94 million yuan [3] - The buyback activity reflects a strategic move by these companies to enhance shareholder value and manage their capital structure effectively [1][2]